-
Je něco špatně v tomto záznamu ?
Adjusting the DNA Interaction and Anticancer Activity of Pt(II) N-Heterocyclic Carbene Complexes by Steric Shielding of the Trans Leaving Group
JK. Muenzner, T. Rehm, B. Biersack, A. Casini, IA. de Graaf, P. Worawutputtapong, A. Noor, R. Kempe, V. Brabec, J. Kasparkova, R. Schobert,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- DNA účinky léků MeSH
- heterocyklické sloučeniny chemie farmakologie MeSH
- lidé MeSH
- methan analogy a deriváty chemie MeSH
- nádorové buněčné linie MeSH
- protinádorové látky chemie farmakologie MeSH
- sloučeniny platiny chemie farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Five platinum(II) complexes bearing a (1,3-dibenzyl)imidazol-2-ylidene ligand but different leaving groups trans to it were examined for cytotoxicity, DNA and cell cycle interference, vascular disrupting properties, and nephrotoxicity. The cytotoxicity of complexes 3a-c increased with the steric shielding of their leaving chloride ligand, and complex 3c, featuring two triphenylphosphanes, was the most efficacious, with submicromolar IC50 concentrations. Complexes 3a-c interacted with DNA in electrophoretic mobility shift and ethidium bromide binding assays. The cationic complex 3c did not bind coordinatively to DNA but led to its aggregation, damage that is not amenable to the usual repair mechanisms. Accordingly, it arrested the cell cycle of melanoma cells in G1 phase, whereas cis-dichlorido[(1,3-dibenzyl)imidazol-2-ylidene](dimethyl sulfoxide) platinum(II) 3a induced G2/M phase arrest. Complex 3c also disrupted the blood vessels in the chorioallantoic membrane of fertilized chicken eggs. Ex vivo studies using precision-cut tissue slices suggested the nephrotoxicities of 3a-c to be clinically manageable.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000086
- 003
- CZ-PrNML
- 005
- 20160126101713.0
- 007
- ta
- 008
- 160108s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.5b00896 $2 doi
- 035 __
- $a (PubMed)26182125
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Muenzner, Julienne K
- 245 10
- $a Adjusting the DNA Interaction and Anticancer Activity of Pt(II) N-Heterocyclic Carbene Complexes by Steric Shielding of the Trans Leaving Group / $c JK. Muenzner, T. Rehm, B. Biersack, A. Casini, IA. de Graaf, P. Worawutputtapong, A. Noor, R. Kempe, V. Brabec, J. Kasparkova, R. Schobert,
- 520 9_
- $a Five platinum(II) complexes bearing a (1,3-dibenzyl)imidazol-2-ylidene ligand but different leaving groups trans to it were examined for cytotoxicity, DNA and cell cycle interference, vascular disrupting properties, and nephrotoxicity. The cytotoxicity of complexes 3a-c increased with the steric shielding of their leaving chloride ligand, and complex 3c, featuring two triphenylphosphanes, was the most efficacious, with submicromolar IC50 concentrations. Complexes 3a-c interacted with DNA in electrophoretic mobility shift and ethidium bromide binding assays. The cationic complex 3c did not bind coordinatively to DNA but led to its aggregation, damage that is not amenable to the usual repair mechanisms. Accordingly, it arrested the cell cycle of melanoma cells in G1 phase, whereas cis-dichlorido[(1,3-dibenzyl)imidazol-2-ylidene](dimethyl sulfoxide) platinum(II) 3a induced G2/M phase arrest. Complex 3c also disrupted the blood vessels in the chorioallantoic membrane of fertilized chicken eggs. Ex vivo studies using precision-cut tissue slices suggested the nephrotoxicities of 3a-c to be clinically manageable.
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a DNA $x účinky léků $7 D004247
- 650 _2
- $a heterocyklické sloučeniny $x chemie $x farmakologie $7 D006571
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a methan $x analogy a deriváty $x chemie $7 D008697
- 650 _2
- $a sloučeniny platiny $x chemie $x farmakologie $7 D017671
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rehm, Tobias
- 700 1_
- $a Biersack, Bernhard
- 700 1_
- $a Casini, Angela $u ‡Department of Pharmacokinetics, Toxicology and Targeting, Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
- 700 1_
- $a de Graaf, Inge A M $u ‡Department of Pharmacokinetics, Toxicology and Targeting, Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
- 700 1_
- $a Worawutputtapong, Pawida $u ‡Department of Pharmacokinetics, Toxicology and Targeting, Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
- 700 1_
- $a Noor, Awal
- 700 1_
- $a Kempe, Rhett
- 700 1_
- $a Brabec, Viktor $u ∥Institute of Biophysics, Academy of Sciences of the Czech Republic, CZ-61265 Brno, Czech Republic.
- 700 1_
- $a Kasparkova, Jana $u ⊥Department of Biophysics, Faculty of Science, Palacky University, 17. listopadu 12, CZ-77146 Olomouc, Czech Republic.
- 700 1_
- $a Schobert, Rainer
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 58, č. 15 (2015), s. 6283-92
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26182125 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160126101836 $b ABA008
- 999 __
- $a ok $b bmc $g 1102367 $s 924292
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 58 $c 15 $d 6283-92 $e 20150729 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20160108
